ImmuCell Corporation (ICCC) - Total Liabilities
Based on the latest financial reports, ImmuCell Corporation (ICCC) has total liabilities worth $15.93 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of ImmuCell Corporation to assess how effectively this company generates cash.
ImmuCell Corporation - Total Liabilities Trend (1989–2024)
This chart illustrates how ImmuCell Corporation's total liabilities have evolved over time, based on quarterly financial data. Check ImmuCell Corporation liquidity resilience to evaluate the company's liquid asset resilience ratio.
ImmuCell Corporation Competitors by Total Liabilities
The table below lists competitors of ImmuCell Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
biote Corp
NASDAQ:BTMD
|
USA | $158.01 Million |
|
Primotec Group Ltd
TA:PRMG
|
Israel | ILA86.27 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
Taiwan | NT$2.94 Billion |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
USA | $21.24 Million |
|
Shinih Enterprise Co Ltd
TW:9944
|
Taiwan | NT$2.35 Billion |
|
Tunas Alfin Tbk
JK:TALF
|
Indonesia | Rp583.40 Billion |
|
Sonel S.A.
WAR:SON
|
Poland | zł27.03 Million |
|
IBKS No2 SPAC
KQ:204840
|
Korea | ₩26.45 Billion |
Liability Composition Analysis (1989–2024)
This chart breaks down ImmuCell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ImmuCell Corporation stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmuCell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmuCell Corporation (1989–2024)
The table below shows the annual total liabilities of ImmuCell Corporation from 1989 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.58 Million | -6.55% |
| 2023-12-31 | $18.82 Million | +29.93% |
| 2022-12-31 | $14.48 Million | +21.80% |
| 2021-12-31 | $11.89 Million | -1.61% |
| 2020-12-31 | $12.08 Million | +24.57% |
| 2019-12-31 | $9.70 Million | -11.71% |
| 2018-12-31 | $10.99 Million | +2.64% |
| 2017-12-31 | $10.70 Million | +115.15% |
| 2016-12-31 | $4.98 Million | +24.79% |
| 2015-12-31 | $3.99 Million | +122.29% |
| 2014-12-31 | $1.79 Million | +14.61% |
| 2013-12-31 | $1.56 Million | -14.76% |
| 2012-12-31 | $1.84 Million | -6.86% |
| 2011-12-31 | $1.97 Million | +34.18% |
| 2010-12-31 | $1.47 Million | +304.88% |
| 2009-12-31 | $362.77K | -25.12% |
| 2008-12-31 | $484.49K | +36.28% |
| 2007-12-31 | $355.52K | -82.50% |
| 2006-12-31 | $2.03 Million | +45.36% |
| 2005-12-31 | $1.40 Million | -22.38% |
| 2004-12-31 | $1.80 Million | +120.64% |
| 2003-12-31 | $816.18K | +46.06% |
| 2002-12-31 | $558.78K | -47.83% |
| 2001-12-31 | $1.07 Million | +18.35% |
| 2000-12-31 | $904.92K | -13.04% |
| 1999-12-31 | $1.04 Million | +15.62% |
| 1998-12-31 | $900.00K | 0.00% |
| 1997-12-31 | $900.00K | -25.00% |
| 1996-12-31 | $1.20 Million | -7.69% |
| 1995-12-31 | $1.30 Million | +8.33% |
| 1994-12-31 | $1.20 Million | +50.00% |
| 1993-12-31 | $800.00K | +60.00% |
| 1992-12-31 | $500.00K | -28.57% |
| 1991-12-31 | $700.00K | +16.67% |
| 1990-12-31 | $600.00K | 0.00% |
| 1989-12-31 | $600.00K | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotaviru… Read more